Company / CapEx per Share
CytomX Therapeutics, Inc. CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.00
FY2025
5-year range
$0.00 / $0.03
FY2021-FY2025
Trend
-58.8%
vs FY2024
Sector context
#166 of 192
Health Care
What the data says
CytomX Therapeutics, Inc.'s capex per share of $0.00 is lower than 86% of companies in the Health Care sector (FY2025). CapEx per Share has declined for 3 consecutive years, from $0.03 in FY2022 to $0.00 in FY2025.
Based on SEC 10-K filings.
0.00 in FY2025 with a 5-year CAGR of -49.9%.
Declined from $0.01 to $0.00 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -60.7%
- 5-Year CAGR
- -49.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 192This company $0.00 Sector average $3.54
▼
-100.0% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s capex per share has declined for 3 consecutive years.
- In FY2025, capex per share decreased 58.8% year-over-year.
- Ranks #166 out of 192 companies in the Health Care sector.
- Peak capex per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.00 | -58.8% |
| FY2024 | $0.00 | -69.0% |
| FY2023 | $0.01 | -52.5% |
| FY2022 | $0.03 | +6.8% |
| FY2021 | $0.02 | -51.5% |
| FY2020 | $0.05 | -34.0% |
| FY2019 | $0.08 | -8.6% |
| FY2018 | $0.08 | +107.4% |
| FY2017 | $0.04 | -32.1% |
| FY2016 | $0.06 | -91.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026